INTRODUCTION
Adoptive T cell therapy has emerged as a promising strategy for the treatment of cancer. [1] [2] [3] [4] [5] [6] [7] The challenges of isolating T cells reactive towards tumor-associated antigens and using such cells in patients with a diversity of human leukocyte antigen (HLA) phenotypes have, to some extent, been overcome through the use of chimeric antigen receptors (CARs). These genetically engineered molecules typically consist of an extracellular antigen-binding domain derived from a monoclonal antibody (Ab), usually in the form of a single-chain variable fragment (scFv), linked via spacer and transmembrane domains to a T cell signaling endodomain, most commonly the CD3ζ chain. 8 CAR-redirected T cells have the capacity to recognize cell-surface tumor targets in an HLA-independent fashion, leading to antigen-specific T cell activation, proliferation, and cytokine production, and the capacity to eradicate tumors in mouse xenograft models. [9] [10] [11] [12] Non-Hodgkin lymphomas (NHL), particularly the indolent B cell lymphomas and mantle cell lymphoma (MCL), are appealing targets for CAR-based immunotherapy because of their susceptibility to T cell-mediated immune effects, as evidenced by long-term remissions following allogeneic stem cell transplantation (SCT). 13, 14 The CD20 antigen on the surface of B-NHL cells is a well-established immunotherapy target for lymphoma, with numerous randomized trials demonstrating improved clinical outcomes in patients treated with anti-CD20 Ab.
We previously reported the results of a phase I clinical trial investigating the use of anti-CD20 CAR + autologous T cells to treat patients with relapsed indolent NHL and MCL. 15 In that study we demonstrated the safety and tolerability of this approach, but found that the ex vivo expansion methods employed were inefficient and that the anti-tumor activity and persistence of the modified T cells were modest.
Numerous pre-clinical studies have demonstrated that CARs
For personal use only. on January 15, 2018 . by guest www.bloodjournal.org From endowed with costimulatory endodomains such as CD28, OX40, or 4-1BB (commonly referred to as "second generation" CARs) augment T cell activity both in vitro and in vivo compared with first-generation CARs lacking costimulation. [16] [17] [18] [19] [20] These enhanced CARs were designed to mimic normal physiology, where both a primary TCR signal and a second costimulatory signal are required for full activation of T cells. The benefit of CAR costimulation was recently confirmed in a clinical trial in which a CD28-containing CAR conferred superior in vivo expansion and persistence compared to a first-generation CAR. 21 Potent anti-leukemic responses were seen in another recent trial in which a 4-1BB domain was incorporated into the CAR. 6 Several groups have combined two costimulatory domains into the CAR construct and shown superior activity in pre-clinical studies. [22] [23] [24] We previously tested multiple CAR configurations in vitro and found that a CAR containing CD28 and CD137 (4-1BB) domains was the most effective in terms of proliferation and cytokine production. 23 We therefore selected this construct for clinical testing and report here the results of a small pilot trial testing this "third generation" CAR.
MATERIALS AND METHODS

Clinical Trial Protocol This clinical protocol was approved by the Fred Hutchinson Cancer Research Center Institutional
Review Board, University of Washington Institutional Biosafety Committee, the NIH Recombinant DNA Advisory Committee, and is supported by the U.S. Food and Drug
Administration BB-IND 13390. This study is registered at www.clinicaltrials.gov as NCT00621452. All patients provided written informed consent in accordance with the Declaration of Helsinki prior to enrolling on the study. Patients were eligible if they had a 25 Modification and expansion of CD20-specific T cells CD20-specific T cells were generated as previously described. 15, 23 Patient PBMC were activated with OKT3 and IL-2, and 4 days later were electroporated with the L29.19.1 plasmid, 23 which encodes a Leu16 (murine anti-human CD20) scFv fused to a human IgG1 C H 2-C H 3 hinge, CD4
transmembrane, intracellular CD28 (with mutated dileucine motif) 26 and CD137 (4-1BB) costimulatory domains, and CD3ζ, under the control of the CMV immediate-early promoter, hereafter denoted as the αCD20-28-BB-ζ CAR, as well as a neomycin resistance gene under the control of an SV40 promoter. Transfected cells were restimulated in 12-15 day cycles using a rapid expansion protocol 15, 27 and selected with G418 during the 1 st , 3 rd , and 4 th stimulation cycles. G418-resistant cells were transferred from flasks to culture bags until the target cell dose was reached. In some instances, batches of cells were cryopreserved during expansion and thawed prior to infusion.
Cytotoxicity Assays
Standard 5-hour chromium release assays were performed as previously described, 15 using the following targets: EL4 (negative control), EL4-CD20 (EL4 cells transfected to express CD20), Granta (CD20 + mantle cell lymphoma line), and Daudi (CD20 + Burkitt lymphoma cell line). Data were analyzed using FlowJo software (Tree Star). CAR expression was assessed by FACS using FITC-conjugated goat anti-mouse IgG F(ab') 2 or PE-conjugated goat anti-human IgG Fc (Jackson Immunoresearch) as previously described. 15, 23 Lymphocyte subsets in serially collected peripheral blood samples were analyzed using multiparameter flow cytometry as previously described. 15 Quantitative PCR to Detect Modified T Cells
Patient PBMC collected at baseline and at serial timepoints after T cell infusions were collected and separated by Ficoll centrifugation and then cryopreserved. Batched cells were thawed and genomic DNA was harvested using a DNeasy Blood and Tissue Kit (Qiagen). The CAR transgene was detected by performing quantitative PCR as previously described, 15 using either a primer amplifying a 111 bp fragment spanning the junction of the CD4 transmembrane region 
Statistics
Telomere lengths were compared using a one-sided paired t-test.
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RESULTS
Study design and patient characteristics
The primary objective of this study was to assess the safety and feasibility of adoptive therapy using autologous T cells genetically modified to express a CD20-specific CAR containing CD28 and 4-1BB costimulatory domains. PBMC collected from study subjects by apheresis were activated by OKT3 and IL-2, and electroporated 3-4 days later with a DNA plasmid encoding a CD20-specific scFv-ζ CAR containing CD28 and 4-1BB intracellular costimulatory domains (denoted αCD20-28-BB-ζ) ( Figure 1A ). Modified T cells were selected with 3 cycles of G418 and expanded using a rapid expansion protocol. 23 The duration of cell culture prior to cell infusion was ≥ 69 days (Table S1) Four patients were enrolled in this study, of whom 3 had relapsed MCL, and 1 had relapsed follicular lymphoma. All patients had received at least 2 prior therapies, and 2 patients had a prior autologous SCT. Patient characteristics are summarized in Table 1 , and a schematic illustration of the study protocol is given in Figure S1 .
Expansion and characterization of modified T cells
The target T cell dose was successfully generated for 3 of the 4 enrolled patients. The cells for patient UPN-01 failed to expand adequately despite 2 attempts at electroporation and expansion, and the patient elected to withdraw from the study rather than receive a reduced cell dose.
Growth curves are shown in Figures 1B and 1C , and cell doses are shown in Table S1 .
T cells modified with the αCD20-28-BB-ζ CAR demonstrated CD20-specific cytotoxicity in vitro ( Figure 1D ) and G418 resistance, indicating expression of the plasmidencoded transgenes. The αCD20-28-BB-ζ CAR was detectable by PCR, but expression was very low, below the limit of detection by flow cytometry and Western blotting (data not shown).
Detailed cell surface marker analysis was performed using flow cytometry to assess the phenotype of ex-vivo expanded cells. The cytolytic potential of the modified T cells declined over time in one patient ( Figure   1D ), which may have been due to functional exhaustion or diminution of CAR expression.
Telomere length was shortened in all patients after ex-vivo expansion compared to CD3 + cells collected at apheresis ( Figure 2C ). Together, these data support findings from other studies that prolonged in vitro culture with multiple rounds of stimulation is detrimental to T cell function, 30, 31 although the degree of telomeric shortening was less than expected, and CD57, a marker of terminal differentiation, was not significantly expressed in any of the expanded T cell products.
Safety and tolerability
The treatment regimen was generally well-tolerated, with most adverse events being predictable grade 1-2 toxicities related to CY and IL-2 (Table 2) . However, one patient (UPN-02) developed fever (39.2 ºC) and orthostatic hypotension immediately following the 2 nd T cell infusion, and fever (39.9 ºC) and mild hypoxemia (90% by pulse oximetry) requiring supplemental O 2 following the 3 rd infusion. In both instances, the toxicities resolved spontaneously after overnight observation in the hospital. The other 2 patients tolerated the T cell infusions without incident.
The most frequent toxicities related to CY were cytopenias, which reached grade 4 in patient UPN-02, a heavily pretreated 80-year old patient, as well as alopecia and fatigue. The most frequent toxicities associated with IL-2 injections were dyspnea, fatigue, and skin injection site reactions. Patient UPN-04 developed a wound infection and cellulitis at the site of the excisional lymph node biopsy (right groin), which required hospitalization for IV antibiotics and was thus classified as a serious adverse event. He recovered without sequelae.
In vivo persistence of infused T cells and localization to tumor sites
Quantitative real-time PCR (Q-PCR) using primers specific for the αCD20-28-BB-ζ CAR transgene was performed on genomic DNA harvested from patient PBMC collected at various timepoints after T cell infusions to assess the duration of in vivo persistence. The peak level of modified T cells detected was 3.2%, 3.0%, and 1.0% for the 3 patients, immediately following the infusions, and subsequently dropped to <1% ( Figure 3A ). Modified T cells were detectable for 12 months in patients UPN-02 and UPN-03, and for 9 months in UPN-04 ( Figure 3B ). The same Q-PCR assay was used to assess trafficking of modified T cells to tumor sites, and these cells were detected at low levels 24-48h after the 3 rd T cell infusion in malignant lymph nodes of It should be noted that B cell aplasia, which is expected following CD20-targeted therapy, 5 was not observed, although B cell levels were very low at baseline for 2 of the 3 patients due to prior therapy ( Figure 6A and Figure S2 ).
For
Immune responses against modified cells
Several gene products of the transferred vector, including the murine scFv, NeoR gene, and junctional epitopes, are potentially immunogenic, and we therefore assessed study subjects for evidence of humoral or cellular immune responses against the infused T cells. We evaluated patient serum samples for the presence of Ab against the transgene products using 2 assays, an ELISA testing Ab binding to the murine Leu16 from which the αCD20-28-BB-ζ scFv is derived, antigens. 2, 36 The optimal regimen and dose intensity of lymphodepleting therapy is not known.
We chose an intermediate dose of CY (1000 mg/m 2 ). Previous studies at our center have suggested that T cell persistence may be improved with administration of low-dose IL-2, 15, 37 which led us to administer 250,000 U/m 2 of IL-2 subcutaneously twice daily for 2 weeks in this study. We evaluated the effect of these adjuvant therapies on lymphocyte subsets, including
Tregs, using multiparameter flow cytometry, and on serum cytokine levels.
This dose of CY resulted in significant lymphopenia of all subsets tested ( Figure 6A-B) .
At the nadir, the absolute CD3 + counts were reduced in the 3 patients by 93%, 80%, and 77%, respectively. The absolute Treg level was reduced by 79%, 96%, and 87% at the nadir for each patient following CY administration. B cell counts were decreased by 80%, 59%, and 85%, respectively. The lymphodepletion was transient, with T cell counts recovering to baseline levels after approximately 12 days. Subsequently, during IL-2 therapy, lymphocyte counts increased predictably to higher than baseline levels.
IL-2 is known to promote Treg proliferation, and as expected, we observed increased
Treg levels following IL-2 injections. In patient UPN-03, the ratio of Tregs to CD4 + and CD8 + cells did not change from baseline, but in UPN-02 and UPN-04, preferential expansion of Tregs was observed, which, in the case of UPN-04, persisted for at least 1 year ( Figure 6C ).
Serum cytokine levels increased in all patients, though the timing varied, correlating with T cell infusions and lymphodepletion in UPN-02, and with IL-2 injections in UPN-03 and UPN-04 ( Figure 6D ). No serum was available from UPN-04 at the time of his clinical response, so it is unknown whether his cytokine levels increased at that time as observed in a recent CD19-CAR study. 6, 38 The homeostatic cytokines IL-7 and IL-15 are of particular interest, and increases in serum levels followed the same pattern as the other cytokines tested. Because IL-15 is transpresented at the cell surface in conjunction with IL-15Rα, 39 serum levels may not be as and IL-2 and were predictable and manageable. These safety results should be interpreted with caution because of the small sample size. It is also possible that a third-generation CAR could engender significant toxicity if expressed at higher levels or in T cells with better engraftment potential, as suggested by a recent study using CD19-41BB CAR-bearing T cells modified using a lentiviral vector.
6,38
The cell production methods used in this protocol resulted in levels of CAR expression that were below the level of detection by flow cytometry and Western blotting. The cause for low expression of the CAR may relate to inefficient gene transfer by electroporation and separate promoters for NeoR and CAR genes, such that G418 resistance does not necessarily select cells Although higher CAR expression would undoubtedly be advantageous, our results suggest that even low CAR expression can produce significant effects, as evidenced by in vitro cytotoxicity against lymphoma cell lines and at least one likely in vivo tumor response. This is supported by past reports of antigen-specific cytotoxicity by CARs expressed below the limit of detection by flow cytometry, 41, 42 and with the observation that as few as 3 TCR-peptide-MHC complexes are sufficient to induce killing of target cells. 43 Furthermore, because activity of CAR + T cells depends upon levels of both antigen and CAR, 40 high CD20 expression on lymphoma cells may "compensate" somewhat for the low CAR expression.
The clinical results of this therapy were promising: 2 patients without evaluable disease remained free of progression for 12 and 24 months, and the third patient had an objective partial response. The contribution of the modified T cells to the progression-free periods of patients UPN-02 and UPN-03 cannot be determined in the absence of measurable disease; however, the median time to progression for relapsed MCL in most clinical trials is approximately 6 months.
For patient UPN-04, the timing of the response was highly suggestive of a T cell-mediated effect, as there was initial mild progression after CY, but more than 3 months later there was a dramatic reduction in several LN. While a spontaneous remission cannot be ruled out, adoptively transferred T cells were detected by Q-PCR in a lymph node following infusions and were present in the patient's peripheral blood before and after the response, albeit at a low level. It is unclear why the response varied among different lymph nodes and why only a partial remission was achieved. Potential explanations include factors in the microenvironment varying from node The development of B cell aplasia is an expected occurrence in CAR trials targeting B cell antigens, which we did not observe. There was no significant reduction in peripheral B cells even in the patient who achieved a partial remission, although this phenomenon was observed in another recent trial as well. 2 It is possible that T cells with low CAR expression are not able to mount a significant response against very low levels of circulating B cells, in contrast to a lymph node with a high density of CD20 + lymphoma cells. This is consistent with previous observations that a sufficiently high level of antigen expression is required to provoke a response in T cells with low CAR expression.
40,41
The recent dramatic responses observed by Kalos et al 38 have naturally led to scrutiny of other CAR trials in an attempt to discern which of the many variables in CAR therapy are the most important. Many differences exist between that study and ours: target antigen, disease target, vector, culture methods, costimulatory domains, lymphodepletion regimen, and use of IL-2. It is difficult to know which of these variables could have been altered in our trial to obtain stronger clinical responses, but we speculate that the low level of surface membrane CAR expression in our study and protracted culture time, potentially leading to a degree of T cell exhaustion, may be two of the most important factors.
We were able to detect the presence of genetically modified T cells in the peripheral blood up to 12 months after infusions by Q-PCR, although the low levels precluded analysis of the CAR expression, phenotype, and functionality of these cells. The peak level of cells we detected around the time of T cell infusions was in the 3-4% range, comparable to other recently published CAR studies. 2, 5, 21 Higher levels of circulating CAR + cells were observed by Kalos et al in 2 patients achieving complete remissions, 38 suggesting that more robust engraftment may be desirable. We also detected modified T cells in malignant lymph nodes in all 3 patients at 24
hours following the final T cell infusion. While the levels of tumor-infiltrating CAR + cells were very low, a later timepoint may have been more relevant for sampling given the more than 3 month delay until response in patient UPN-04.
This trial was not designed to discern whether the inclusion of costimulatory domains improves upon the functionality of first-generation CAR + T cells. The improvement in persistence from 2 months in our previous study to 12 months, along with apparently enhanced anti-tumor activity suggest a possible beneficial effect of the costimulatory domains, although this could also be partially due to CY lymphodepletion. It is worth noting that the in vitro cytotoxicity of the T cell product for UPN-02, which consisted primarily of CD4 + T cells, was equivalent to that of the other patients with CD8 + -predominant products. Robust cytolytic activity can be acquired by CD4 + cells cultured in vitro with IL-2 44 and has been observed with ex vivo cultured CD4 + CAR T cells in clinical trials as well. 2 As with our previous study, we found no evidence of cellular or humoral immune responses against the infused cells. This contrasts with other recent CAR studies that found antitransgene immune responses directed against the NeoR gene or scFv epitopes. 45, 46 This may be partially explained by the low level of transgene expression observed in our study, but it is more
For personal use only. on January 15, 2018. by guest www.bloodjournal.org From likely due to the impaired immunity of lymphoma patients that mitigates against rejection of genetically modified T cells. The small number of patients treated on this trial makes it difficult to draw definitive conclusions about the immunogenicity of our CAR protein, but it is worth striving to minimize potential immunogenicity in designing future CARs by using humanized Abs, minimizing junctional regions, and avoiding xenogeneic genes such as those encoding for antibiotic resistance.
The optimal lymphodepletion regimen for adoptive T cell therapy is not known. Recent clinical trial results suggest that transfer of T cells with high activity and capacity for in vivo proliferation may obviate the need for high-intensity lymphodepletion strategies. 6, 38 The intermediate dose of CY we used led to effective (~80-90%) levels of lymphodepletion of all T cell subsets, including regulatory T cells, with minimal toxicity, and may be a reasonable regimen to consider in future trials. Low-dose IL-2 injections have been found to prolong T cell persistence, but as demonstrated in this and other studies, IL-2 also leads to expansion of Tregs, and therefore other cytokines such as IL-15 may be more advantageous.
One of the primary endpoints of this study was to assess feasibility. The generation of CD20-specific T cells using the methods described was technically feasible, but difficult to sustain. Gene transfer by electroporation of naked plasmid DNA is highly inefficient and necessitates antibiotic selection of transfectants during expansion. This process results in prolonged and intensive use of many resources (personnel, cGMP facilities, etc.) and is not practical for scaling up to treat larger numbers of patients. Furthermore, it likely impairs T cell functionality and potential for in vivo expansion, as evidenced by a decrease in cytotoxicity in one patient, shortened telomeres, and low levels of engraftment in vivo. Additionally, taking into account patients treated in our previous trial, 15 cells failed to expand adequately in 4 of 13 patients. No characteristics emerge as clear risk factors for expansion failure among these patients, aside from expanding T cells as clones as opposed to bulk cultures (Tables S2 and S3 ).
In view of these problems, in future trials we plan to use lentiviral vectors for gene delivery and shorter ex vivo culture times, which we anticipate will prove to be much more efficient and feasible, and will likely result in higher CAR expression and enhanced anti-lymphoma activity. Conflict-of-interest disclosure: M.C.J. is inventor of a licensed patent related to the CD20 CAR plasmid and a co-founder and equity holder in ZetaRx Biosciences, Inc. that has licensed the patent. Abbreviations: MCL = mantle cell lymphoma, FL = follicular lymphoma, R = rituximab, CHOP = cyclophosphamide, doxorubicin, vincristine, and prednisone, ASCT = high-dose therapy followed by autologous stem cell transplantation, GCD = gemcitabine, carboplatin, and dexamethasone, RT = radiotherapy, PR = partial response, SD = stable disease, CR = complete response For personal use only. on January 15, 2018. by guest www.bloodjournal.org From
